Remove Cannabinoids Remove Pharmaceutical Remove Treatment
article thumbnail

Cannabinoids for Scleroderma

Project CBD

Pharmaceutical researchers have their sights set on developing a drug that bypasses CB1 while boosting CB2. Referred to as a “selective CB2 agonist ,” such a compound would appear to have potential as a treatment for scleroderma.

article thumbnail

The Science Behind Medical Marijuana: Exploring Cannabinoids and Their Therapeutic Effects

MMJ Recs

This article delves into the science behind medical marijuana, focusing on cannabinoids, the active compounds found in the cannabis plant, and their remarkable therapeutic effects. We’ll explore the diverse range of cannabinoids and their health benefits, providing insights into how these compounds are revolutionizing healthcare.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Cannabis Cancer Connection

Project CBD

There is a growing body of anecdotal and scientific evidence that the “major cannabinoids” tetrahydrocannabinol (THC) and cannabidiol (CBD), certain “minor cannabinoids” (some without a name), and other cannabis compounds have antineoplastic action against cancer cells. THC binds to two types of cannabinoid receptors, CB1 and CB2.

article thumbnail

Anebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication

Cannabis Law Report

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. There is a large and growing need to treat acute cannabinoid intoxication with 1.7 million cannabinoid-related emergency department visits in the U.S. About Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals, Inc. Rex Merchant.

article thumbnail

GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex

Cannabis Law Report

We are delighted by today’s decision from the MHRA for this new indication, which represents a significant step forward for TSC patients in the UK, many of whom may benefit from this new treatment,” said Chris Tovey , Executive Vice President, Chief Operating Officer and Managing Director, Europe & International at Jazz Pharmaceuticals.

article thumbnail

Prohibition Publish 2nd Ed Of The Pharmaceutical Cannabis Report

Cannabis Law Report

The use of cannabinoids in the treatment of medical conditions offers major opportunities and challenges to anyone operating in the space. In Europe, there is a clear trend towards the use of more precise formulations of unapproved cannabis products as well as pharmaceutical products.

article thumbnail

Clinical Trial: Cannabinoid Administration Via a Metered-Dose Inhaler Is Safe and Effective for Chronic Pain Patients

NORML

Thus, it enables individualization of medical cannabis regimens that can be evaluated pharmacokinetically and pharmacodynamically by accepted pharmaceutical models.” Additional information regarding cannabinoids and pain appears online h ere.